Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1633 1645
This examiner grants 77% of resolved cases
Jennifer E. Graser is an examiner in Tech Center 1600, specifically working in Art Unit 1633. She has a high volume of 1043 resolved cases, which provides a very reliable dataset for analysis. The examiner's allowance rate is 76.6%, a figure that indicates a generally favorable environment for applicants. Furthermore, the 23.5% interview lift suggests that direct communication is a highly effective way to advance an application toward allowance.
The median days to allowance for cases under her review is 886. This 886-day timeline is relatively efficient, providing applicants with a clear expectation of the duration of the prosecution process in Art Unit 1633. The 23.5% interview lift is a significant factor, as it shows that interviews can provide a substantial boost to the 76.6% allowance rate. With 1043 resolved cases, the examiner's performance metrics are well-established and offer a clear guide for practitioners.
In Tech Center 1600, the 76.6% allowance rate and 886-day median pendency suggest a productive and efficient examination process. Practitioners should consider the 23.5% interview lift as a key strategic tool. By leveraging these metrics, applicants can better navigate the specific requirements and tendencies of Examiner Graser.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 19644831 | MICROORGANISM HAVING FOREIGN NICOTINAMIDE NUCLEOTIDE TRANSHYDROGENASE INTRODUCED THEREINTO AND METHOD FOR PRODUCING L-AMINO ACID OR DERIVATIVE THEREOF USING SAME | Non-Final OA | CJ CHEILJEDANG CORPORATION |
| 18851628 | ANTIGEN DELIVERING SALMONELLA FOR USE AS A TUMOR HOMING BEACON TO REFOCUS PREEXISTING, VACCINE GENERATED T CELLS TO COMBAT CANCER | Non-Final OA | University of Massachusetts |
| 18722030 | METHODS AND COMPOSITIONS OF TREATING BIOLFILM-RELATED DISEASES | Final Rejection | UNIVERSITY OF ROCHESTER |
| 18261568 | Staphylococcus aureus Antigen-Based Nucleic Acid Vaccines | Final Rejection | University of Rochester |
| 17620633 | BACTERIA-ENGINEERED TO ELICIT ANTIGEN-SPECIFIC T-CELLS | Final Rejection | The Board of Trustees of the Leland Stanford Junior University |
| 18711047 | TREATMENT OF VISCERAL PAIN | Non-Final OA | IPSEN BIOPHARM LIMITED |
| 18562157 | IMPROVED BIOTECHNOLOGICAL METHOD FOR PRODUCING GUANIDINO ACETIC ACID (GAA) BY INACTIVATION OF AN AMINO ACID EXPORTER | Final Rejection | Evonik Operations GmbH |
| 18895960 | STRAINS, COMPOSITIONS AND METHODS OF USE | Non-Final OA | L'Oreal S.A. |
| 18671007 | Non-Toxin Antigens For Clostridioides Difficile Vaccine | Non-Final OA | The United States Government As Represented by the Department of Veterans Affairs |
| 18684124 | COMPOSITIONS AND METHODS FOR GENERATING TICK IMMUNITY | Non-Final OA | Yale University |
| 19054649 | ATTENUATED BORDETELLA BRONCHISEPTICA STRAINS, ORAL VACCINES CONTAINING THE ATTENUATED STRAINS, AND METHODS OF MAKING & USE THEREOF | Non-Final OA | Boehringer Ingelheim Animal Health USA Inc. |
| 18721985 | Method for Preparing Outer Membrane Vesicles | Non-Final OA | GLAXOSMITHKLINE BIOLOGICALS SA |
| 18728807 | BIFIDOBACTERIUM INFANTIS FORMULATIONS | Non-Final OA | International Centre for Diarrhoeal Disease Research, Bangladesh |
| 18704175 | PROBIOTIC LACTOBACILLUS STRAIN COMPOSITIONS AND APPLICATIONS THEREFOR INCLUDING FOR LEAKY GUT AND INFLAMMATION | Non-Final OA | BiomEdit, LLC |
| 18284513 | IMMUNOGENIC FUSION PROTEIN | Final Rejection | MINERVAX APS |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy